In 1981, it was estimated that 815,000 new cases of invasive cancer would be diagnosed, with 420,000 estimated deaths. These incidence estimates are based on rates obtained from the National Cancer Institute Seer Program (1973) (1974) (1975) (1976) (1977) .' More than 50% of the patients with the diagnosis of cancer will receive radiation therapy as definitive management, as an adjuvant to surgery or chemotherapy, or for palliation. It is estimated by Powers'' that more than 201,000 patients diagnosed of cancer in 198 1 will be treated for palliation. The basic aim of palliative radiation therapy would be to prolong the process of comfortable living.
In recent years, much of the emphasis in the radiation therapy literature has been on the curative utilization of ionizing radiations, either alone or in combination with other treatment modalities. Special emphasis has been given to the combined radiation therapy and radiation sensitizers, to radiation combined with hyperthermia, and to the explorations in high energy particle radiation therapy. Supported Despite this emphasis on curative techniques and newer modalities, radiation therapy remains an important tool in the palliation of the patient with cancer. An excellent example of this treatment program is the alleviation of pain achieved by treatment of metastatic disease to the bone. Pain is an intolerable burden to the patient and has a severe adverse effect on the quality of life. The use of analgesics, including the narcotic agents, is often of limited value, especially in those patients whose life expectancy is long (Table 1) .
Several studies have demonstrated that the expected life span for the patient with metastatic bone disease is not short; it is common for patients to live many years despite the presence of multiple metastatic lesions to bones.' A prime example of this particular situation is the older woman with metastatic cancer of the breast to multiple bones, as well as older men with metastatic cancer of the prostate to multiple bones. Most chemotherapeutic programs using either cytotoxic drugs or hormonal agents are not effective in relieving bone pain.
In the adult patient, the so-called boneseeking tumors are those that arise primarily from the lung, breast, prostate, kidney, stomach, pancreas, colon, bladder, cervix, melanoma, testis, and carcinoid tumors. In 1981, more than 122,000 new cases of lung cancer will be diagnosed and at least half of these patients can be expected to develop bone metastasis at some point during the course of their disease process. During the same year, more than 110,000 new cases of cancer of the breast will be diagnosed and at the In view of these numbers alone, the importance of radiation therapy in the management of metastatic bone disease is obvious. The vertebral vein system as described by Batson2 offers the model to explain the frequency and idiosyncratic pattern of metastatic bone disease. The Batson vein system constitutes thin-walled veins with no effective valves, a sluggish circulation, and many storage sites. Metastases from pelvic and lower abdominal disease primaries can occur at any point along this system without involving the portal, vena caval, or pulmonary venous systems. Therefore, this offers a logical explanation for the frequency of bone metastases in the absence of other overt organ involvement with cancer.
Radiation therapy can be used in the management of symptoms related to bone metastases with minimal complication when precise treatment planning techniques are employed and attention to detail pursued. Prior to the 1950s, most radiation therapy was administered using orthovoltage equipment with beam energies in the range of 100-400 kv. A theoretical advantage in using this instrumentation was that within the energy range, there was an increased radiation absorption in bone as compared to surrounding soft tissue structures. However, tumor dosages were limited for other reasons, especially the limited tolerance of skin at these energy levels.
With the advent of Cobalt-60 teletherapy devices and subsequently, megavoltage devices, e.g., linear accelerators and betatrons, higher doses of radiation could be delivered safely to deep-lying structures without major limitations from skin or soft tissues. For more superficial structures, e.g. ribs, the advantages of orthovoltage technique still
The impact of radiation on bone and cartilage has been described by Rubin and Casarett.I3 Mature cartilage and bone are quite radioresistant, which contributes to the low incidence of abnormalities following radiation. With megavoltage techniques, a pathologic fracture or osteonecrosis secondary to radiation rarely occurs unless there is a predisposing condition, e.g., infection, major alterations in blood flow to the irradiated organ, or associated major trauma. In large measure, the postradiation changes in bone are secondary to vascular damage from the disease process itself, traumatic episodes, infection, or major alterations in arterial blood flow. Fortunately, the incidence of radiationinduced bone sarcomas is extremely low and related to high dose radiation techniques, and in the case of palliative treatment for bone metastasis, of no major ~o n c e r n .~ The diagnosis of bone metastasis is rarely difficult. The patient usually presents with bone pain, a history of cancer, and one of the bone-seeking tumors as a primary site. Most frequently, conventional roentgenograms will show typical osteoblastic or osteolytic abnormalities, although a major portion of the bone must be destroyed beforehand. Radionuclide bone scanning is the most sensitive diagnostic study for the demonstration of apply. When evaluating patients, those who have a single area of bone metastasis with no other evidences of metastatic disease must be distinguished from those who have multiple areas of metastatic disease in bone or soft tissue, and treatment decisions relative to management must consider the differentiation.
Radiation therapy is usually performed on areas of metastatic bone disease, but only if the site is painful. Occasionally, a patient may present with pain in one area of bone with localized tenderness, but have a normal bone scan and normal radiographic findings. If this patient already has documented bone metastases at other sites, the present painful area can be assumed to be from metastatic disease and treated with radiation therapy. If no other evidences of metastatic disease are found, a clinical dilemma develops and biopsy is sometimes necessary to identify the true state of the abnormality.
In 1895, Roentgen described X-rays and almost immediately the biologic effects were recognized as a potential benefit in the treatment of the patient with cancer. With the publication in November 1895, radiation therapy was utilized for the management of bone metastases in January 1896 by Grubbe in Chicago, for a patient with cancer of the breast. Currently, vast clinical experience has accumulated, with many publications identifying the potential for significant or complete relief of pain in at least 80% of patients treated for bone metastasis.
The reparative process following radiation therapy has been summarized by Matsubayashi." In his study, bone specimens obtained at autopsy were used to evaluate the histopathologic effect of radiation on bone and the results were clinically correlated with X-rays of living patients. The reparative process involves several steps, starting with degeneration and necrosis of the cancer cells following radiation therapy, with replacement by proliferative fibrous tissue. Collagen fibers then aggregate within a loose fibrous stroma with a rich blood supply. These fluffy strands of aggregated collagen fibers become calcified and mineralized. Through this process, woven bone trabeculae are formed with osteoblastic rimming. Finally, this woven bone structure matures and is replaced by lamellar bone. There is radiographic evidence of recalcification in metastatic lesions, usually occurring within three to four months after completion of the radiation therapy program. If the patient survives more than six months, an almost normal bone structure may often be r e~t o r e d .~
The prime purpose in irradiating areas of bone metastasis is not only to achieve palliation of the symptoms, but also to give a dosage adequate to ensure long-term control without the need for subsequent treatments. In those patients who have a single-area bone metastasis without any other areas of metastatic disease to bone or soft tissues, and with the primary under control, more aggressive treatment would be warranted when compared to those patients who have multiple bony metastases with or without soft tissue metastatic disease and without regard to the control of the primary tumor. In the patient who has a single metastasis, radiation therapy dosages should be adequate to ensure not only relief of symptoms, but also the greatest potential for long-term control without regrowth of tumor in the treated site.
MATERIALS AND METHODS
At the Hahnemann Medical College and Hospital, the records of more than 500 patients treated for bone metastasis during the period from 1970 to 1979 were reviewed.14 From the records available, the authors were able to evaluate the response to radiation therapy for 384 treatment sites. The average age of the patients was 57 years (range, 20-85 years). Almost 75% of the patients were women, explained by the large number of patients who had breast cancer. Fifty-three per cent of all the sites treated were secondary to breast cancer. Other primary tumors were prostate in 11% of the cases, lung in 9%, colon in 5% and other or unknown sites in 22% The other sites included leiomyosarcoma, renal cell carcinoma, lymphoepithelioma, and squamous cell carcinoma of the cervix.
The policy pursued within the institution has been to use relatively large fields in the treatment volume, encompassing the painful and known area of disease with a generous margin around it. Various technical factors are considered, including shaping of the fields to protect vital structures and the general arrangement of the field. The average tumor dose delivered to each treatment site was 2950 rad in 17 days (range, 2000 rad in seven days for those patients with multiple widespread bone metastases to 5000 rad in 32 days for those patients with single sites of metastasis unassociated with metastatic disease in other locations). The preference pursued was not to use short courses of radiation therapy given in a one to five day period; an immediate good response in terms of pain relief would result, but these treatment programs are not adequate to maintain long-term control in the irradiated volume. The Radiation Therapy Oncology Group' has reported various treatment schemes. In patients treated in a oneweek period as many as 18% subsequently failed and needed retreatment to the initial site within 12 months after the first course of radiation therapy. This contrasted significantly with an 8% failure rate in those patients treated in a two-week period (Tables 2 and 5) . The same Radiation Therapy Oncology Group study studied cases of solitary bone metastasis and the difference was more dramatic; patients given 2000 rad in one week demonstrated a 22% failure rate ( I 3/60 retreatment when the initial program was 4050 rads given in three weeks. These data substantiate clearly the preference for performing palliative radiation therapy in a two to three week period.
RESULTS
T h e response to treatment in t h e Hahnemann series was graded as follows: ( I ) good or excellent; (2) fair; ( 3 ) little or no response. A good or excellent response was defined as one in which no analgesics were required after completing the radiation treatment program. A fair response indicated a reduction in the amount of analgesic medications required but not total elimination of pain. Little or no response indicated no change or an increase in pain. In the evaluation of the Hahnemann series, 72% of the patients were rated a good or excellent response 30 days after treatment, 14% a fair response, and 14% a little or no response. Statistically there was no difference in pain relief with respect to the site of the primary tumor or the specific bone site treated (Tables 3 and 4). Approximately 17% of the treatment sites were subsequently retreated because of recurrent pain. All were in patients with breast cancer and other long-term survivors who had received a low dosage in short periods.
Some investigators have proposed the use of half-body or total body radiation therapy in the treatment of patients with diffuse Other 88 6 6 metastatic bone disease.6 Although some of the results in terms of pain relief appear impressive at first glance, the duration of pain relief is frequently very short, usually less than three months. Furthermore, pulmonary and hematologic tolerance often make this an impractical approach in those patients who have advanced disease and have already received programs of multiple chemotherapeutic agents. The utilization of such wide field radiation therapy techniques for bone metastasis remains an experimental project.
DISCUSSION
Radiation therapy plays a major role in the management of patients who have a pathologic fracture. Following internal fixation of the fracture, a course of postoperative radiation therapy is important to give. Without this program the tumor will con- tinue to grow and the surgical appliance, in those patients with long-term survival, will become displaced or not as effective in maintaining anatomical alignment. The authors recommend that following the surgical procedure, including hip replacement for metastatic disease, 3,000 rad in two weeks be administered to the site of the pathologic fracture and residual tumor. This can be started within ten to 14 days without a significant risk of complication or a failure to heal.
In those patients who have extensive metastatic disease with thinning of the cortex of weight-bearing bones, the potential for fracture becomes a major concern in management. It is preferable to treat these situations in prospect without waiting for the fracture to occur or for pain to develop. It has been recommended that radiation therapy alone might be utilized in association with limited immobilization of the affected portion until healing can occur. A more practical approach is to achieve internal fixation on an anticipatory basis, after which postoperative radiation therapy can be given ten to 14 days later. The results from such anticipatory treatment are far more appropriate than those achieved when pathologic fracture occurs and emergency management needs pursued.
Occasionally, the patient cannot be cleared medically for surgery and in those instances palliative radiation therapy should be pursued without internal fixation.
SUMMARY
Radiation therapy is an important palliative treatment in the management of patients with metastatic bone disease. Excellent results are obtained following radiation therapy to the involved area when generous margins are employed with appropriate megavoltage devices and time-dose-fractionation/protraction. Often an objective response to treatment occurs, as evident by roentgenograms and by pathologic evaluation. Whether the patient's expected life span is relatively short or relatively long, the approach to treatment of bone metastasis must be done within the context of a multidiscipline management. Close cooperation is necessary among radiation oncologists, medical oncologists, orthopedic surgeons, and physiatrists. Radiation therapy for local persistent symptoms relative to bone metastases is an effective technique for achieving long-term control of localized pain without the need for retreatment. Those patients who have a single metastasis with no other evidences of metastatic disease, and who are best treated aggressively, should be differentiated from those patients who have bone metastases as part of a general pattern of metastatic disease where more conservative radiation therapy techniques would be pursued.
